Literature DB >> 29970246

Apparent diffusion coefficient measurement in luminal breast cancer: will tumour shrinkage patterns affect its efficacy of evaluating the pathological response?

D Zhang1, Q Zhang1, S Suo1, Z Zhuang1, L Li1, J Lu2, J Hua3.   

Abstract

AIM: To determine which region of interest (ROI) placement method of apparent diffusion coefficient (ADC) measurement has the best performance for predicting pathological complete response (PCR) at two cycles of neoadjuvant chemotherapy (NAC) according to different tumour shrinkage patterns of luminal breast cancer and to assess the evaluative accuracy of ADC value combined with other clinicopathological indicators.
MATERIALS AND METHODS: Sixty-one patients who underwent NAC for histopathologically confirmed breast cancer were enrolled in this retrospective study. The ADC values of different shrinkage patterns (concentric shrinkage, nest or dendritic shrinkage, and mixed shrinkage) for tumours shown by diffusion-weighted imaging (DWI) were measured independently using three ROI placement methods (single-round, three-round, and freehand). Intraclass correlation coefficients (ICCs) were used to assess the interobserver variability in the ADC values. Multivariate logistic regression analysis was performed to identify the independent predictors of PCR.
RESULTS: The best placement method found was single-round ROI in all the patients (AUC=0.863). When analysed separately, the effectiveness results differed: the single-round method was optimal for concentrically shrinking tumours (AUC=0.970); the freehand method was optimal for nest or dendritically shrinking tumours (AUC=0.714); and the three-round method was optimal for mixed shrinking tumours (AUC=0.975). Multivariate logistic analysis showed that oestrogen receptor (ER), ΔADC% and tumour diameter reduction (ΔD%) were independent factors in evaluating the PCR.
CONCLUSION: The methods for measuring ADC values vary across different shrinkage patterns of luminal tumours. ΔADC%, ER and ΔD% were independent factors for evaluating the PCR.
Copyright © 2018 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29970246     DOI: 10.1016/j.crad.2018.05.026

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  7 in total

Review 1.  Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer.

Authors:  Huan Wang; Xiaoyun Mao
Journal:  Drug Des Devel Ther       Date:  2020-06-18       Impact factor: 4.162

2.  Molecular Mechanism of Secondary Endocrine Resistance in Luminal Breast Cancer.

Authors:  Minhua Wu; Jinhua Ding; Limu Wen; Yuxin Zhou; Weizhu Wu
Journal:  Biomed Res Int       Date:  2021-03-16       Impact factor: 3.411

Review 3.  Factors affecting the value of diffusion-weighted imaging for identifying breast cancer patients with pathological complete response on neoadjuvant systemic therapy: a systematic review.

Authors:  Kay J J van der Hoogt; Robert J Schipper; Gonneke A Winter-Warnars; Leon C Ter Beek; Claudette E Loo; Ritse M Mann; Regina G H Beets-Tan
Journal:  Insights Imaging       Date:  2021-12-18

4.  Using the apparent diffusion coefficient histogram analysis to predict response to neoadjuvant chemotherapy in patients with breast cancer: comparison among three region of interest selection methods.

Authors:  Xiaochuan Geng; Dandan Zhang; Shiteng Suo; Jie Chen; Fang Cheng; Kebei Zhang; Qing Zhang; Lan Li; Yang Lu; Jia Hua; Zhiguo Zhuang
Journal:  Ann Transl Med       Date:  2022-03

5.  Meta-Analysis of Shrinkage Mode After Neoadjuvant Chemotherapy for Breast Cancers: Association With Hormonal Receptor.

Authors:  Chun-Hui Zheng; Kai Xu; Wen-Ping Shan; Ya-Kun Zhang; Zhi-De Su; Xiang-Jin Gao; Yu-Jue Wang; Jian-Yu Qi; Xiao-Yan Ding; Chun-Ping Wang; Yong-Sheng Wang
Journal:  Front Oncol       Date:  2022-04-04       Impact factor: 5.738

6.  Prediction of Tumor Shrinkage Pattern to Neoadjuvant Chemotherapy Using a Multiparametric MRI-Based Machine Learning Model in Patients With Breast Cancer.

Authors:  Yuhong Huang; Wenben Chen; Xiaoling Zhang; Shaofu He; Nan Shao; Huijuan Shi; Zhenzhe Lin; Xueting Wu; Tongkeng Li; Haotian Lin; Ying Lin
Journal:  Front Bioeng Biotechnol       Date:  2021-07-06

7.  Pretreatment apparent diffusion coefficient does not predict therapy response to neoadjuvant chemotherapy in breast cancer.

Authors:  Alexey Surov; Andreas Wienke; Hans Jonas Meyer
Journal:  Breast       Date:  2020-06-26       Impact factor: 4.380

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.